Skip to main content
RACURA ONCOLOGY LTD logo

RACURA ONCOLOGY LTD — Investor Relations & Filings

Ticker · RAC ISIN · AU000000RAC3 LEI · 9845004A1AE3E97Q1296 ASX Professional, scientific and technical activities
Open in API
Filings indexed 950 across all filing types
Latest filing 2026-05-27 Director's Dealing
Country AU Australia
Listing ASX RAC

About RACURA ONCOLOGY LTD

https://racuraoncology.com/

Racura Oncology Ltd is a clinical-stage entity focused on the development of precision oncology therapeutics. The organization specializes in the inhibition of the Fat Mass and Obesity-associated (FTO) protein, a key regulator of m6A RNA methylation involved in cancer progression. Its primary therapeutic candidate, Bisantrene, is a small molecule inhibitor designed to address FTO-driven pathways in acute myeloid leukemia and various solid tumors. The company’s research program explores the cardioprotective benefits and anti-tumor efficacy of its lead compounds, targeting specific molecular drivers of disease. By focusing on the intersection of RNA epigenetics and targeted therapy, the company seeks to overcome treatment resistance and improve patient outcomes in oncology.

Recent filings

Filing Released Lang Actions
Appendix 3Y - Dr Daniel Tillett 2 pages 197.0KB
Director's Dealing Classification · 95% confidence The document is an ASX Appendix 3Y notice disclosing a director’s change of relevant interests in securities (the exercise and disposal of options and acquisition of shares by Director Daniel Tillett). This is a director’s personal share transaction filing, matching the ‘Director’s Dealing’ category.
2026-05-27 English
Application for quotation of securities - RAC 8 pages 20.8KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 2A ‘Application for quotation of securities’ announcing the issue and quotation of new ordinary shares following option exercises. It provides detailed share issue and capital structure changes. This corresponds to a Share Issue/Capital Change announcement (SHA).
2026-05-27 English
Appendix 3Y - Dr Daniel Tillett 2 pages 197.2KB
Director's Dealing Classification · 95% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice,” detailing the director’s personal transactions in company securities (exercise of options and acquisition of shares) and obligation under listing rule 3.19A.2. This matches the definition of insider/director transactions reporting.
2026-05-25 English
Application for quotation of securities - RAC 8 pages 20.8KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 2A application for quotation of securities following conversion of options to ordinary shares. This is a direct announcement of a share issue/capital change (new securities issued and quoted). It does not contain financial statements but details of securities issued, fitting the Share Issue/Capital Change category.
2026-05-25 English
Racura Oncology Final Option Expiry Reminder 7 pages 887.0KB
Share Issue/Capital Change Classification · 75% confidence The document is an ASX announcement reminding optionholders about the expiry of piggyback options and providing instructions to exercise them. It relates directly to the company’s capital structure and potential share issuance upon exercise. It is not a financial report, transcript, or director dealing notice, but an announcement concerning share issue/capital change. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-20 English
Application for quotation of securities - RAC 8 pages 20.8KB
Share Issue/Capital Change Classification · 95% confidence The document is the ASX Appendix 2A “Application for quotation of securities,” detailing the issuance and quotation of new shares following conversion of options. This is a formal announcement of a share issue/capital structure change, corresponding to category ‘Share Issue/Capital Change’ (SHA).
2026-05-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.